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The enzyme hyaluronidase from human synovial fluid was
partially purified using gel-filtration and chromotography
on a hydroxylapatite column. A 4.1-fold purification of
. . . .
-4
hyaluronidase having a specific activity of 1.1 x 10
ymol/min/mg was obtained. The enzyme was inhibited by the
gold complex Auranofin, and the steroid derivative,
22-ketocholesterol oxime.
It was shown that the complexes differed in their
ability to inhibit the enzyme. The rate constants and
equilibrium inhibition constants were calculated. The K
value for Auranofin was 8.78 mM and its rate constant was
-1
0.049 min . The K value for 22-ketocholesterol oxime was
11.86 mM. Kinetic analyses demonstrated an apparent
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Arthritis and rheumatism are frequently used words which
are often employed without a clear understanding as to their
underlying meaning or knowledge of their causes. Arthritis
is the general term used when the joint itself is the major
site of the rheumatic disease, while rheumatology is the
study of the rheumatic diseases, including arthritis,
fibrositis, rheumatic fever, bursitis, neuralgia, gout, and
other conditions producing stiffness, soreness, or somatic
2 .pain. According to the estimates obtained from numerous
3
surveys, and quoted by the Arthritis Foundation in 1982,
there are more than 36,000,000 persons in the United States
suffering from some sort of arthritis or related disease.
Rheumatoid arthritis is one of the most prevalent types
of rheumatic disease and has received increasing interest by
various disciplines within the scientific community. It is
relatively common, and in its more serious forms it can lead
to severe crippling and disablity. The origin of rheumatoid
arthritis has eluded detection despite a great expenditure
of resources and energy. It appears that the pathology of
rheumatoid arthritis is undoubtedly related to an

inflammatory response involving the immune system, and the
initiating event which triggers this response is most likely
2
a specific etiologic agent.
Recently, the interest of most workers have focused on
immunologic phenomena as the instigators of the primary
pathogenetic mechanisms in the causality of rheumatoid
. .
4-6
arthritis. The most common way to account for
inflammation in a rheumatoid joint, in the absence of any
known etiologic agent, is to invoke an altered immune
reaction. There is evidence to suggest that immunologic
events occur in rheumatoid arthritis, particularly in the
joints. Rheumatoid factors have been observed with
rheumatoid arthritis. Immune complexes formed between
rheumatoid factors and y globulin are phagocytized by
7 8leukocytes in vitro or in the synovial fluid in the joint.
As a result of phagocytosis of particulate complexes,
9leukocytes may degranulate releasing their lysosomal and
hydrolytic enzymes into the joint fluid, possibly provoking
local inflammation.
Analysis of synovial fluid plays a major role in the
diagnosis of joint disease. Synovial fluid is basically an
ultrafiltrate of the plasma combined with a
mucopolysaccharide (hyaluronate) that is synthesized by the
10
cells of the synovial membrane. The functions of the
synovial fluid are to lubricate the joint space and
11transport nutrients to the articular cartilage.

Destruction of the synovial fluid with age or in a disease
state may lead to the development of degenerative joint
disease (osteoarthritis) . Inflammatory joint fluids contain
lytic enzymes that produce depolymerization of hyaluronic
acid greatly impairing the lubricating ability of the
11fluid.
Every year additional enzymes have been found in
elevated concentrations in rheumatoid joint effusions
leading to an already impressive list. Examples
illustrating the diversity of these enzymes are given in
Table 1
.
There is indirect evidence to support the idea that the
enzymes are not circulatory since their activities in the
sera of rheumatoid patients are found to be within normal
limits. ' It has been shown in inflammatory diseases
27that synovial cells, leukocytes infiltrating the synovial
18 2 8
tissue, and cartilage cells are all involved in the
increase of the afforementioned enzymes in synovial fluid.

Table 1. Enzymes in Synovial Fluid of Patients with
Rheumatoid Arthritis.
Enzyme Reference
Lactate dehydrogenase (EC 1.1.1.27) 12
Pyruvate kinase (EC 2.7.1.40) 12
Aspartate aminotransferase (EC 2.6.1.1) 12
5'
-Nucleotidase (EC 3.1.3.5) 13
Leucine aminopeptidase (EC 3.4.11.1) 13,14
Pepsin (EC 3.4.23.1) 15
Trypsin (EC 3.4.21.4) 15
Acid phosphatase (EC 3.1.3.2) 16
Alkaline phosphatase (EC 3.1.3.1) 17
Cathepsin D (EC 3.4.23.5) 18
Cathepsin G (EC 3.4.21.20) 19
Lysozyme (EC 3.2.1.17) 19
a- Mannosidase (EC 3.2.1.24) 20
N-Acetyl-3-D-glucosaminidase (EC 3.2.1.30) 21,22
B -Glucuronidase (EC 3.2.1.31) 23
Myeloperoxidase (EC 1.11.1.7) 19
Collagenase (EC 3.4.24.3) 24
29 . .Swann classified, on the basis of their origin, the
synovial fluid macromolecular constituents as follows: a)
the constituents derived from blood ; b) the substances
secreted by the joint tissues; and c) the products that were
derived from the catabolism of the joint. Enzymes and
regulators of enzymatic activity have been shown to
originate from each of these sources. While it is probable
that many of the enzymes that are featured predominantly in
diseased joints are derived from infiltrating leukocytes,

recent work has made it clear that in some cases they are
derived from the non-vascularized intra-articular tissues
1
8
such as synovium and cartilage.
30Hyaluronidase, discovered by Duran-Reynals,
constitutes a family of enzymes. They can be grouped into
31
various types according to their mechanism of action.
Hyaluronoglucosaminidases (EC 3.2.1.35),
hyaluronoglucuronidases (EC 3.2.1.36) and hyaluronate lyases
32(EC 4.2.2.1) comprise several isoenzymes. For example,
testicular and lysosomal hyaluronidases are both of the
aminidase type, but the former has an optimum pH of 6.0 and
33the latter a pH of 3.5.
Hyaluronidases can also be separated into two groups
according to their physiological role. They can function in
the metabolism of "self" hyaluronic acid, and yet act upon
"non-self" substrates. The first group of hyaluronidases
comprise the lysosomal and serum hyaluronidases which are
characterized by an in vitro narrow acidic pH range of
activity. The second group, the testicular, bacterial, and
venom hyaluronidases, are enzymes with an in vitro broad pH
34
range of activity whose optimal pH is close to neutrality.
Hyaluronidases hydrolyse the (8 1-4) glycosidic bonds in
a number of different substrates such as hyaluronic acid,
. . 35
chrondroitin 4-sulfate and chrondroitin 6-sulfate.
(Figure 1) These substances are essential for maintaining

the integrity of the extracellular fluid matrix. Alteration
of their structure and concentration may affect and modulate
o CL "3 *"7
numerous cell functions, such as, phagocytosis, ' *"
,, 38 , . , . . 39 , . ^ . . 40, 41 .adhesion, mobility, proliferation, and
42 43differentiation. ' The hyaluronic acid-hyaluronidase
44
system takes part in the process of dermis permeability,
45 46 47
embryonic development, tumor development, cellular
48 49immune response, ' and in the control of the angiogenisis
50factor. It also plays an important role in such processes
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Figure 1. Action of Hyaluronidase on Different Substrates.

8Hyaluronidase in the present study was obtained from
human synovial fluid and canine synovial fluid. The
properties of this enzyme from different sources have been
thoroughly investigated by Meyer, Hoffman and Linker. It
has been shown that hyaluronidase from rat liver ' and
from fetal rat bone is localized in the lysosomes of
those tissues. The liver enzyme was shown to give an even
numbered of oligosaccharide products, which are identical to
64those produced by the testicular enzyme. Aronson and
Davidson isolated hylauronidase from the lysosomes of rat
liver. The enzyme was purified 1300 fold by ammonium
sulfate precipitation, chromotography on hydroxyapaptite and
chromotography on Sephadex G-100. The purified fraction gave
two peaks, the slower of which yielded a single band using
acrylamide gel electrophoresis while the faster of the two
was yellow and contained no enzymatic activity. The
molecular weight of the slower peak enzyme was calculated to
be 89,000 based on sedimentation equilibrium data.
35 ...Joy et al investigated liver hyaluronidase using pigs
as their source of the enzyme. Their technique of
purification varied from that of Aronson. A single band
was observed after electrophoresis on polyacrylamide gel
yielding an enzyme with an apparent molecular weight of
70,000 and an isoelectric point of 5.0. The substrate
specificity of this enzyme was the same as that for bovine
testicular hyaluronidase ; however, the Km and Vmax values

of the porcine liver enzyme were significantly lower for all
substrates (hyaluronate, chrondroitin 4-sulfate,
35
chrondroitin 6-sulfate) . The amino acid composition of
69 .hyaluronidase isolated from bee venom by Kenemy is
illustrated in Table 2.
Table 2. The Amino Acid Composition of Purified
Bee Venom Hyaluronidase
Amino acid Amount in hyaluronidase found Reported (b)


















The results obtained on an LKB 4400 automatic amino acid
analyser are expressed as a molar ratio, taking leucine as
10. 68
(a) Results reported by Kemeny.
(b) Results reported by King.
Aspartic acid 15.6 16.6
Threonine 7.0 5.6
Serine 6.7 6.6


















The precise role and specificity of hyaluronidase from
different sources has yet to be demonstrated. Stephens et
70 . .
al, compared the properties of human synovial fluid and
serum hyaluronidase in an attempt to elucidate the origin of
this enzyme and explain the lack of correlation of the
enzyme activity with inflammatory indices. Bovine
testicular hyaluronidase which has been used by many workers
as a model system for examining the effects of drugs and
other agents on human hyaluronidase has also been
71-73investigated for its properties.
Purification of the human synovial enzyme was
acomplished by ammonium sulfate fractionation, agarose gel
permeation chromatography and hydroxylapatite gel
chromotography . Serum and synovial fluid enzymes gave
essentially the same pH-activity relationship and behaved as
typical lysosomes. Their pH optimum was approximately 3.4
with no activity produced above pH 5.0 while bovine
testicular hyaluronidase had optimal activity at pH 5.0 and
70
very low activity at pH 3.4.
74 .According to Stephens et al, in contrast to the
findings dealing with exopolysaccharides, the hyaluronidase
activity in fluids obtained from the pathological groups
consisiting of rheumatoid and osteoarthritic patients were
found to be similar. The hyaluronidase activity levels of
both the rheumatic and osteoarthritic samples were always
less than that for normal serum. Hyaluronidase in synovial

11
fluid does not appear to be a product of inflammatory cells
within the joint. In view of its low molecular weight
estimated to be 60,000 by column chromotography, it is
likely that the enzyme may be derived from a remote source
74
such as diffusion from serum. Serum hyaluronidase is
. . 75 . . .indeed very similar in properties to the synovial fluid
enzyme and is known to be inhibited in the same manner as
the serum enzyme by a substrate universally present in
"7 £
mammalian blood.
This result, coupled with the requirements for acidic
conditions makes it unlikely that the 3-enzyme system
74(Figure 2) is active in synovial fluid in vivo. Rather,
the lysosomal environment within phagocytic cells would
appear as the most favorable one for glycosaminoglycan
74
catabolism by the mechanism outlined.
Different types of drugs have been used in controlling
the symptoms of rheumatoid arthritis with no one drug
leading to a complete cure. There is a wide and
unpredictable variation of patient response to the different
drugs. At the present time, non-steroidal anti-inflammatory




ENZYME DEGRADATION OF HYALURONATE
HYALURONIDASE










GA = GLUCURONIC ACID
Figure 2. Scheme for the Mechanism of Total Degradation of Hyaluronate
by Rheumatoid Synovial Fluid. High molecular weight substrate
is first cleaved by hyaluronidase , and the oligosaccharides
produced are further attacked by exopolysaccharidases
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Among rheumatologists in the United States, gold is
currently the most popular long-term suppressive drug for
. . 77the treatment of rheumatoid arthritis, and it has been
used successfully for the past sixty years. Gold is
7 8
available in parenteral as well as oral form. During
parenteral administration, gold binds to albumin, and then
tends to concentrate in the liver, kidney, spleen and lymph
79 ...
nodes. Gold also concentrates in synovial tissues but not
in cartilage. Autoradiography has shown increased
concentrations of gold in subsynovial membranes in the area
8
of perivascular infiltration of mononuclear cells.
Myochrysine (gold sodium thiomalate) and Solganal
(aurothioglucose) are the preparations of choice for
77parenteral use.
The exact mechanism of gold action is unknown. Besides
antibacterial properties, gold exhibits partial suppressive
phagocytic activity on macrophages and neutrophils. Gold
stabilizes lysosomal membranes, thus inhibiting enzyme
release. Most investigators, in recent years, suggest both
an immunostimulative and an immunosuppressive effect of
8
1
gold; thus, it may be an immunoregulating agent. Biggs et
82
al recently demonstrated that all parenteral gold
compounds, that is, gold sodium thiomalate, aurothioglucose,
and sodium aurothiosulfate, (Figure 3) bind to the serum
proteins at the same rate and exhibit similar affinity
constants and labelling capabilities. The mechanism of this

14
reaction is not well understood, but it is likely to involve
the well-recognized property of the gold compounds' ability
to interact avidly with the sulfhydryl side chains of
818 4 85proteins. ' Lorber et al reported that gold shows a
concentration-dependent affinity for other serum compounds
including immunoglobulins and complement. Finally,
injectable gold shows affinity for other circulating
elements of the blood including erythrocytes and
87lymphocytes
.
Auranofin is a synthetic gold compound in which the
central atom of gold is stabilized by covalent bonding with
8 8two side groups, a phosphine ligand and a sulfur ligand.
Unlike parenteral gold, Auranofin exhibits cellular-binding
rather than almost exclusively binding to serum proteins.
From recent studies, it was demonstrated that 40% to 66% of
89-91
mtramuscualar gold is associated with cells, primarily
erythrocytes following oral administration. The balance was
found to be largely bound to albumin. Cell specific binding
might possibly represent part of a biologic reservoir or
transport system as discussed by Stephens.
Auranofin has proven to be quite effective in reducing
carrageenan-induced edema in a model of inflammation as
92 ...
shown in the studies by Walz et al . Inhibition of edema
formation of 62% to 80% were obtained with varying doses of
the drug. In contrast, gold sodium thiomalate and gold

15
sodium thioglucose did not significantly inhibit the rat paw
formation edema.
43 '
Corticosteroids have played a prominent role in the
therapy of rheumatic diseases since their discovery in the
late 1940s. The various metabolic, anti-inflammatory, and
immunosuppressive effects of the corticosteroids are the
result of a common mode of action on the cells involved in
93
rheumatoid inflammation. Some steroids are known to
inhibit the production of proteinases such as collagenases




In an active site-directed mechanism, the enzyme binds
with the inhibitor in forming a non-covalent complex prior
. . 97to forming a covalent enzyme-inhibitor complex. Kitz and
98 .Wilson derived an equation that is based on the
appropriate assumption that the enzyme is a reagent, as
contrasted to the less rigorous assumption of steady
99 . .
state. In affinity labeling,
k
i k 3
E + I '








it is assumed that formation of the reversible complex
(E * I) is in rapid equilibrium compared to the formatiom of
the irreversibly inactivated enzyme (E * X) that (I) >> (E) ;

and that when the reaction mixture is assayed for enzymatic
activity, E and E * I produce full activity while E - X is
inactive. Then
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/[I]) + In [E]
T (9)
If the logarithim of enzymatic activity
[E] - [E-X] = [E] + [E*I] is plotted against time, the
observed first order rate constants, k . , may be calculated
obs' J
from the slope or by k . = 0.693/t- ,« and is related to the
desired constants by equation 10.
k
obs " V I1/(K I + [I1 » (10)

17
Since this equation predicts hyperbolic saturation
kinetics, a plot of 1/k , versus 1/[I] allows a graphical
estimation of k~ and K .
The purpose of this investigation was to isolate,
purify, and partially characterize the enzyme hyaluronidase
and then study the inhibition of the enzyme with a gold
complex, Auranofin and compare it with a well known steroid,








































The following materials were used,








N, N, N' , N' , -Tetramethylethylenediamine
Trizma 7-9










Smith Kline & French Laboratories .
Auranofin



















































Human synovial fluids were obtained from the Hughston
Sports Medicine Hospital and the Medical Center, Doctor's
Hospital in Columbus, Georgia and the Internal Clinical
Laboratories in Atlanta, Georgia. Animals under
investigation at the Small Animal Clinic, College of
Veternary Medicine, Auburn University, Auburn, Alabama were
the source of canine synovial fluid.
Stored, frozen synovial fluid samples were thawed and
centrifuged at 9,000 x g at 4 C in a refigerated centrifuge
to remove cellular debris. The supernatant was collected and
stored at -20 C for further experimentation.
Hyaluronidase Activity
Hyaluronidase was assayed by a modification of the
method of Reisseg, Strominger, and Leloir. The substrate
stock solution of hyaluronic acid was 1.25 mg/ml and it was
prepared by dissolving 20 mg of the hyaluronic acid in 16 ml
of distilled water. Two hundred fifty yl of the 1.25 mg/ml
substrate solution was mixed with 250 yl of 0.2 M formate
buffer at pH 4.0 and 25 yl of the enzyme solution. The
prepared samples were then incubated at 37 C for twenty
hours. One hundred yl of 0.8 M potassium tetraborate was
added to each assay tube and heated in vigorously boiling
water for three minutes and cooled in tap water. Three ml
of dimethylaminobezaldehyde reagent were added and after

22
mixing, the tubes were heated for twenty minutes at 37 C.
The tubes are then cooled, and the amount of
N-acetylglucosamine groups released were measured at 585 nm.
To calculate the concentration of the product
N-acetylglucosamine, the gram molecular weight was taken to
be 221.2.
Protein Concentration and Specific Activity
The protein concentration was determined using the
Bradford protein assay. This method was based on the
observation that the maximum absorbance for an acidic
solution of Coomassie Brilliant Blue G-250 shifts from 465nm
101 102to 595 nm when binding to proteins. The Bradford
protein assay is commercially available as a kit from
Biorad; containing lyophilized protein (bovine serum
albumin) and a dye reagent provided as a five-fold
concentrate. The dye was diluted, four parts distilled
water to one part dye, and then filtered through Whatman
number one filter paper. The standard assay contained
5-500 yg of protein. The absorbance was measured on the
spectrophotometer at 595 nm at 25 C. Specific activity was
defined as the ymol/min/mg of protein at 25 C.
Purification of Hyaluronidase
Human synovial fluid collected from different patients
were pooled and stored for further use. The pooled portions
were diluted 1:1 volumetrically with ice cold buffer

23
containing 0.1 M acetic acid, 20% sucrose, 1.0 mM EDTA and
0.01% Triton X-100 at pH 5.0. A Sorvall refrigerated
centrifuge with a SS-34 rotor was used to centrifuge the
homogenate at 12,000 x g for 40 minutes at 4 C. The
supernatant solution was filtered through glass wool to
remove any particles floating in solution and then adjusted
to pH 5.0 by addition of 0.5 M acetic acid buffer. This
solution was utilized for the first step in the
purification. Batches of 50-70 ml each were used in the
following procedure.
Sephadex G-75-120 Chromotography
103The method descibed by Reiland was used to prepare
the Sephadex beads. Two liters of distilled water were used
to suspend twenty-five grams of Sephadex G-75-120 powder,
which was then heated in a water bath at 70 C for three
hours and allowed to stand overnight. The supernatant
solution was discarded and the remaining slurry was degassed
and poured into a 2.5 X 110 cm glass column. A 0.01 M
sodium acetate buffer containing 1.0 mM EDTA and 0.1 M NaCl
at pH 5.0 and 4 C was used to equilibrate the packed column
for 24 hours at which time a flow rate of 30 ml/hr was
established. Seventy ml of the supernatant solution from
the previous step was applied to the top of the column and
the sample was eluted with the same equilibrating buffer at
a flow rate of 25 ml/hr. The eluents were collected in 5.0

24
ml fractions and analyzed first for protein content in the
spectrophotometer at 280 nm. The hyaluronidase activity for
each protein fraction was measured as previously described.
The enzyme fractions were pooled and used in the next
purification step.
Hydroxylapatite Chromotography
The active enzyme fraction from the G-75 column was
applied to a 1.5 X 4.5 cm column of hydroxylapatite
(Calbiochem) which had been equilibrated with 10 mM sodium
phosphate buffer containing 1 mM EDTA at pH 7.0 for six
hours. The column was eluted with the same equilibrating
buffer at a flow rate of 18 ml/hr and then eluted with 200
ml of a 10-250 mM sodium phosphate gradient. One and
one-half ml fractions were collected at a flow rate of 18
ml/hr. The fractions were analyzed for protein content and
hyaluronidase activity as previously descibed.
Gel Electrophoresis
Polyacrylamide gel electrophoresis was performed on the
samples using slab gels. Theoretically, electrophoresis
through polyacrylamide gels should lead to enhanced
resolution of a sample compound because the separation is
based on both molecular sieving and electrophoretic
mobility. Polyacrylamide gels were prepared by the free
radical polymerization of acrylamide and the crosslinking
agent, N-N' -methylene-bis-acrylamide . Chemical

25
polymerization is controlled by an initiator/catalyst
system, ammonium persulfate, N, N, N' , N' -tetramethylenediamine
104(TEMED)
.
The gel stock solutions were prepared according to the
method of Davis. The solutions were stored at 4 C for
two weeks while the ammonium persulfate was freshly prepared
prior to use. Equilibration and degassing of the solutions
were completed before polymerization with the catalyst. The
glass plates were pretreated with Kodak photo-flo 200
solution prior to usage to enhance eveness of gels.
To perform the polyacrylamide gel electrophoresis the
following reagents were prepared.
1. 10% separating gel:
13.5 ml of a 22.6% acrylamide and a 0.6%
N, N' -methylene bis acrylamide solution
15 ml of 0.375 M Tris buffer at pH 8.7
0.025 ml TEMED
2. 3.5% Stacking gel:
34 ml of a 22.6% acrylamide and a 0.6%
N, N' -methylene bis acrylamide solution
34 ml distilled water
7.5 ml of a .0125 M Tris buffer at pH 6.8
3. Catalyst:
A 10% solution of ammonium persulfate was made by







Coomassie Blue G-250 solution
6. Sample buffer:
0.08 M Tris at pH 6.8
1 M sucrose
0.01% bromophenol blue (tracking dye)
0.02 M EDTA
7. Stain:






Procedure for Preparing the Gels
A 10% acrylamide gel was prepared as described earlier.
The polymerization was initiated by the addition of the
catalyst. After completion of the polymerization, the slab
gel was layered with the stacking gel. The protein samples
were diluted 1:1 with the sample buffer and electrophoresis
was allowed to proceed for six hours at 8 ma/slab gel. The
proteins were located using the Commassie Blue G-250 stain
which was added to the gels with the protein samples. The

27
gels were placed in the fixing solution for fifteen minutes
and then in the staining solution for overnight incubation.
The stained gels were washed in the destaining solution for
several hours with continuous shaking to destain the gel
background. The finished gels were placed in plastic bags
containing 7% acetic acid and stored at 37 C.
Inhibition studies
Hyaluronidase was tested for inhibition with a gold






Hyaluronic acid was used as the substrate for the studies.
Both the steroid and gold complex were first dissolved in
absolute ethanol and further diluted in a 0.2 M phosphate
buffer, pH 4 . because of their insolubility in aqueous
media. A constant concentration of enzyme (0.1 mg/ml) was
mixed with different gold and steroid concentrations. The
concentrations of Auranofin were varied from 1.0 mM to 10
mM. Fifty yl aliquots of gold complex-enzyme mixture were
tested over a period of twenty-four hours for enzyme
activity. The steroid concentrations were varied from

28
1.25 mM to 7.5 mM. The steroid enzyme-inhibitor mixtures
were tested according to the procedure followed for
Auranofin. Control experiments were conducted in the same
buffer-ethanol mixtures. The control involved the use of
the enzyme hyaluronidase without an inhibitory compound.

III. RESULTS
Enzyme Analysis of Synovial Fluid
The hyaluronate digestion catalyzed by the enzyme
hyaluronidase is shown in the following equations.
H
2OH











As the enzyme catalyses the cleavage of the acetal
bonds, N-acetylglucosamine end groups are formed and
measured as described in the assay procedures. The activity
was recorded as absorbance/hr and then converted to
ymol/min of N-acetylglucosamine using the standard curve
(Figure 4) . The protein concentration was measured using
the Bradford protein assay kit. The absorbance of protein
was then converted to mg of protein by using the BSA
standard curve shown in Figure 5. The specific activity of
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Figure 5„ Standard Curve of Absorbance Versus Concentration




The hyaluronidase activity in unpurified canine synovial
fluid from 13 dogs was determined and the tabulated
activities are shown in Table 3. A thirteen-fold increase
was observed in the activity of the 4 rheumatic dogs as
compared to the 7 normal dogs. In addition, 2 synovial
samples tainted with blood contained approximately 40 fold
greater hyaluronidase activity than normal synovial fluid
and three times greater activity than fluid from rheumatic
dogs
.
Table 3. Comparison of Mean Hyaluronidase Activities
in Canines





Synovial Fluid 2 6. 02+. 38
*Unit = umole/min
Human Synovial Fluid
The purification of human synovial hyaluronidase by gel
filtration thru Sephadex G-75-120 is illustrated in Figure
6. When measured at 280 nm, the elution profile revealed 3
protein peaks but only one peak contained activity. Peaks A
& B showed no hyaluronidase activity while peak C (tubes




0.49 X 10 units/mg. One peak containing catalytic
activity was obtained from the hydroxylapatite
chromotography of the G-75-120 preparation. The elution
profile is shown in Figure 7. The single peak yielded a
-4
specific activity of 1.1 X 10 units/mg which represents a
four fold increase in specific activity. Table 4
Table 4. Purification Procedure for Human
Synovial Fluid Hyaluronidase
Step Activity Protein Specific ~
(ymoles/min/ml) (mg/ml) Activity X 10
(ymole/min/mg)
Homogenate
(10,000 x g) 0.000866 32.1 0.028
G-75-120 0.00076 15.5 0.049
Hydroxylapatite 0.000376 3.4 0.11
Gel Electrophoresis
Polyacrylamide gel electrophoresis was performed after
purification to determine the purity of the enzyme. The
protein bands were identified by staining the gels in a
solution of Commassie Brilliant Blue, a dye which
preferentially binds to proteins (Figure 8) . From the
polyacrylamide gel electrophoresis, a single band of the
purified hyaluronidase was obtained (Figure 9) . Using a
series of proteins as molecular weight standards, a purified
sample of hyaluronidase was estimated to have a molecular



























Figure 6. Chromotography of Human Synovial Fluid Hyaluronidase
on Sephadex G-75-120 Column. The supernatant from
step 1 was applied onto a 2.5 x 110 cm column and
eluted with 0.01 M acetate buffer containing 0.01%
triton X-100, 1.0 mM EDTA, at pH 5„0.
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Figure 7. Chromotography of Human Synovial Fluid Hyaluronidase
on Hydroxylapatite., The dialysate from step 2 was
applied onto a 1.5 x 4„5 cm column, previously
equilibrated with the dialysis buffer, 10 mM sodium
phosphate, 1 mM EDTA at pH 7.0. The enzyme was eluted
with 200 ml of a linear gradient (10-250 mM) sodium





Hyaluronidase from human synovial fluid was inhibited by
the gold complex Auranofin. The rate of inactivation is
shown in Figures 10. A slow and gradual loss of enzyme
activity was observed over a period of 2 4 hours. The
control uninhibited hyaluronidase did lose 3% activity
within 24 hours, however, the other curves have been
corrected for the loss.
With the use of the semilog plot of remaining activity,
a linear relationship was developed to an inactivation level
of 45% as seen in Figures 10 & 11. Using the double
reciprocal plot (Figure 12), Auranofin yielded a K of 8.78
mM and a k~ of 0.049 min
The steroid derivative, 22-ketocholesterol oxime, was
analyzed for inhibition and kinetics. The rate of
inactivation is shown in Figure 13. It was observed that
22-ketocholesterol oxime induced an inhibition of enzyme
activity which plateaued by six hours. A semi-log plot of
data in Figure 13 did not yield straight lines indicating
the absence of the irreversible step leading to formation of
the covalently bonded E-X complex (Figure 14) . A
Lineweaver-Burk plot of the steroid induced inhibition
yielded parallel straight lines thereby suggesting an





2. Rheumatoid Arthritis (Human)
3. Rheumatoid Arthritis (Canine)
4. Normal (Canine)
Figure 8. Protein Staining of the Gel Electrophoresis for








2. Sephadex G-75-120 Peak C
3. Protein Standards
Figure 9. Protein Identification Bands of Hyaluronidase
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Figure 14. Semilog Plot of Data From Figure 13 Against










Figure 15. Lineweaver-Burk Plot of the Inhibition of
Hyaluronidase by 22-Ketocholesterol 0xime o
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Secondary plots of the reciprocals of Vmax , against the




= 1/VmaxK [I] + 1/Vmax (12)
The kinetic constants for the inhibition of
hyaluronidase by 22-ketocholesterol oxime evaluated directly
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Figure 16. Secondary Plot Computed from the Lineweaver-Burk
Curves in Figure 15.

IV. CONCLUSION
Hyaluronidase was purified from human synovial fluid
following a modified procedure based on the work of Aronson
and Davidson . Using the modified procedure, human
synovial fluid produced relatively smaller quantities of
active enzyme. Upon completion of the purification, a
-4
specific activity of 1.1 X 10 ymole/min/mg was obtained
which corresponds to a 4-fold increase in purification.
Comparison of the specific activity of hyaluronidase from
human synovial fluid characterized in the present study with
hyaluronidase isolated from rat liver, honey bee venom, and
pig liver is difficult due to the different assay
procedures. The marked difference in assay conditions of Joy
et al 35 (0.1 M sodium citrate buffer, pH 4.5, 0.15 M NaCl)
for pig liver and of Kemeny et al (0.1 M sodium acetate
buffer, pH 6.0, 0.15 M NaCl) for honey bee venom versus
those used in the present study (0.2 M sodium phosphate
buffer, pH 4.0) preclude a direct comparison of enzyme
activity.
The G-75-120 chromotography produced three separate
peaks; the first two with no enzyme activity while the third
peak contained the enzymatic activity. On elution through
the hydroxylapatite column, one enzyme peak was produced




Aronson and Davidson, the purification procedure through
the hydroxylapatite column allowed enhanced purification
during each experiment but the loss of the enzyme varied
from 30% to 75%.
The purified hyaluronidase was quite stable during the
assay procedures using a 0.2 M formate buffer, pH 4.0. After
the required twenty hour incubation time, the enzyme had no
notable loss of activity. Polyacrylamide gel
electrophoresis of the purified enzyme yielded only one
major band as seen in Figure 8.
A separate study was conducted to compare the profile of
hyaluronidase in human versus canine synovial fluid. The gel
electrophoresis patterns, Figure 9, produced common protein
bands from both human and canine synovial fluid samples. As
107
seen in previous studies, from our laboratory, it has
been demonstrated that the acid phosphatase enzyme activity
levels in human synovial fluid are higher in rheumatic
synovial fluid as compared to normal fluid. The findings of
the present study showed a thirteen fold increase in
hyaluronidase activity from the synovial fluid of rheumatic
dogs as compared to the non-rheumatic control dogs.
(Table 3) .
The levels of hyaluronidase in rheumatoid synovial
fluids of humans do not significantly differ from those of
74
osteoarthritic fluids. It has been suggested that the




synovial cells. In a comparative study, two samples of
canine synovial fluid tainted with blood produced
hyaluronidase levels three to forty times the amount seen in
corresponding synovial samples (Table 3) . With a determined
molecular weight of 48,000 for human synovial fluid
hyaluronidase as compared to 45, 000 for serum albumin, it is
possible that both canine and human synovial fluid
hyaluronidase are derived by diffusion from the blood as
74discussed by Stephens, et al.
After purification, the inhibition of hyaluronidase by a
gold complex, Auranofin, and a steroid derivative,
22-ketocholesterol oxime, was investigated. Both compounds
had inhibitory effects on the enzyme. Auranofin caused a
steady decrease of hyaluronidase activity over the
twenty-four hour period as seen in Figure 10. The initial
rate constants were calculated from the reciprocal plot
(Figure 12). As outlined in the previous section (eq.2),
the evaluation of K is dependent on the formation of the
reversible complex (E * I) which is in equilibrium with the
free enzyme, and then reacts slowly to form the stable
covalently bonded E - X complex. The rate constant k^
represents the irreversible activation and this step
represents the covalent bonding of the Au to a nucleophile
such as S or possibly the N of a histidine, lysine or
arginine. Several studies have shown that the above binding
is seen in reactions of Pt(II) as well as Au(III)">
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complexes containing sulfhydryl groups at the active site.
Our studies showed that Auranofin had a 10% to 55%
inhibitory effect on hyaluronidase activity (Figure 10)
.
In this study, the steroid exhibited behavior suggestive
of a reversible type of association with the enzyme
hyaluronidase. Employing an inhibition equilibrium study,
we were able to obtain results and calculate associated
parameters. As discussed in previous publications from our
lab, the mode of inhibition by 22-ketocholesterol oxime may
be best explained by the location of the nitrogen atom in
the aliphatic hydrocarbon chain of the steroid derivative
since the rest of the molecule is unreactive. The actual
107
role of the nitrogen atom has yet been determined.
The results of the present studies show a definite
difference between the inhibition by the gold complex versus
the steroid derivative. Auranofin probably has an
intermolecular interaction with the enzyme due to the
formation of the covalent complex E - X rather than the weak
association complex. This can be supported by the high K
value of 8.78 mM and the relatively small rate constant of
0.05 min . The small rate constant may represent the long
time requirement exhibited by the gold complex to elicit the
permanent inhibitory effects. The steroid derivative had a
K of 11.86 mM and showed formation of a reversible
equilibrium complex. As other studies have shown, steroids
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elicit temporary relief in inflammation with the possiblity
of forming an equilibrium complex.
The results obtained in the present study dealing with
Auranofin and 22-ketocholesterol oxime are similar to those
107 .
obtained by Haddad in our laboratory. She evaluated the
kinetics of Auranofin-induced inhibition of acid phosphatase
obtained from human synovial fluid. She showed Auranofin
inhibited acid phosphatase with a K of 0.545 mM and a k~ of
-1
22.7 mm . Since both studies show weak inhibitor-enzyme
association as illustrated by similar K values and slow
rates of covalent bond formation as illustrated by similar
k3 values for Auranofin, it is suggestive that the
interaction between the enzyme and gold complex is more
likely to involve a weak nucleophile such as nitrogen rather
than a sulfhydryl group or at least not a fully accessible
sulfhydryl group as is expected for stronger gold-enzyme
interactions. However, these observations need to be tested
by further experimentation. When comparing the K's of the
steroid derivative with the gold complex (as calculated from
the Lineweaver-Burk plots Figure 12 & 16) , the similarity in
107the values with the findings of Haddad suggest a similar
bonding profile. It is possible that both inhibitory
complexes initially associate with the same groups on the
enzyme or by a similar mechanism. However, the specific
mechanisms of intermolecular interactions must be shown by
further experimentation. After both inhibitors form the
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initial equilibrium association for a period of time, the
gold eventually forms a stable complex with a strong bond
while the steroid is released. It is hard to assess what
role the geometry of the molecules might have but may be
reflected in the observed differences.
Therefore, it can be concluded that both the gold
complex and the steroid derivative are inhibitors of
hyaluronidase . With the use of a suitable test model and
further experimentation, it may be possible to elucidate the
molecular interactions of various anti-inflammatory drugs.
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